Researchers evaluated the efficacy and safety of talazoparib in the neoadjuvant setting in a phase 2, nonrandomized, single-arm, open-label study.
Durvalumab improved invasive disease-free survival, distant disease-free survival, and overall survival.
The signature was prognostic for locoregional recurrence.
Rates of SARS-CoV-2 infection and COVID-19-related death were similar among patients receiving cytotoxic and non-cytotoxic therapy.
Endocrine therapy was associated with fewer adverse events.
Black patients were more likely than White patients to have distant metastases.